IAMA Therapeutics’ Post

View organization page for IAMA Therapeutics, graphic

1,557 followers

Exciting News! We're thrilled to announce that we've initiated our First-in-Human Clinical Trial for the treatment of neurodevelopmental disorders. In this landmark achievement, we've successfully dosed the first two cohorts of subjects and we are moving forward to the third one in a first-in-human Phase 1 clinical trial of IAMA-6, our promising small molecule designed to target NKCC1. IAMA-6 is our lead clinical program, representing a breakthrough in addressing neurodevelopmental disorders. This highly selective small molecule, designed for oral administration, targets NKCC1-associated neuronal hyperexcitability. Preclinical studies have demonstrated its safety and efficacy, paving the way for its evaluation in a Phase 1 clinical trial. The therapeutic potential of IAMA-6 extends to a spectrum of neurodevelopmental disorders, including epilepsy and other central nervous system disorders, offering hope for patients and families affected by these conditions. Learn more about our mission at https://lnkd.in/d7ayaMWE #IAMAtherapeutics #Neurodevelopment #ClinicalTrial #Neuroscience #Biotech

  • No alternative text description for this image
Paul Frohna

Chief Medical Officer & Translational Medicine Enthusiast | Biotech Board Member & Advisor

8mo

Fantastic to see this novel therapeutic approach from IAMA hit the clinic!

Like
Reply

To view or add a comment, sign in

Explore topics